论文部分内容阅读
本文目的是肯定口服肼苯哒嗪长期降低小儿原发性心肌病后负荷的长期效果。经M型和二维超声心动图及心血管造影确诊为原发性心肌病(包括心内膜弹力纤维增生症和扩张型心机病患儿共16例,年龄3～48个月。一旦确诊,立即给抗充血治疗。其中16例同时给与肼苯哒嗪治疗,另12例为对照组。对照组除不用肼苯哒嗪外,均给同样的治疗。结果静脉用肼苯哒嗪0.2～0.25mg/kg后,,心脏指数从3.18±0.29增加到3.75±0.39L/min/m~2(P<0.1),全身血管阻力从18.68±2.47降低到15.4
The purpose of this paper is to confirm the long-term effect of oral hydralazine in long-term load reduction in children with primary cardiomyopathy. M-and two-dimensional echocardiography and cardiovascular angiography diagnosed as primary cardiomyopathy (including endocardial fibroelastosis and dilated cardiomyopathy, a total of 16 children aged 3 to 48 months, once diagnosed, Immediately to the anti-hyperemia treatment.Among them, 16 cases were treated with hydralazine and the other 12 cases as the control group.The control group were given the same treatment except hydralazine.Results The intravenous hydralazine 0.2 ~ After 0.25mg / kg, the cardiac index increased from 3.18 ± 0.29 to 3.75 ± 0.39L / min / m 2 (P <0.1) and systemic vascular resistance decreased from 18.68 ± 2.47 to 15.4